Related Experiment Video

Updated: Jun 12, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Anti-tumour activity of fotemustine and protons in combination with bevacizumab

Lela B Korićanac1, Jelena J Zakula, Ivan M Petrović

  • 1Vinca Institute of Nuclear Sciences, Belgrade, Serbia.

Chemotherapy
|June 17, 2010
PubMed
Abstract

Insights

Fotemustine, bevacizumab, and proton irradiation reduce aggressive melanoma cell viability and proliferation. These treatments induce apoptosis and G1 or G2 cell cycle arrest, offering potential therapeutic strategies for resistant melanoma.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Pharmacology

Background:

  • Metastatic melanoma is an aggressive cancer with high therapeutic resistance.
  • Current treatments for melanoma have limited efficacy against resistant cell lines.
  • HTB140 human melanoma cells exhibit resistance to conventional therapies.

Purpose of the Study:

  • To investigate the in vitro anti-proliferative effects of fotemustine (FM), bevacizumab, and proton irradiation on resistant human melanoma cells.
  • To evaluate the impact of these agents, individually and in combination, on melanoma cell viability, proliferation, apoptosis, and cell cycle distribution.

Main Methods:

  • In vitro study utilizing HTB140 human melanoma cells.
  • Sulforhodamine B assay for cell viability assessment.
  • 5-bromo-2-deoxyuridine assay for cell proliferation analysis.
  • Flow cytometry for cell cycle distribution and apoptosis examination.

Main Results:

  • All tested treatments (fotemustine, bevacizumab, proton irradiation) significantly reduced melanoma cell viability and proliferation.
  • Apoptosis levels increased notably with fotemustine, proton irradiation, or combination treatments.
  • Proton irradiation and specific combinations induced G1 phase arrest, while other treatments led to G2 phase accumulation.

Conclusions:

  • Fotemustine, bevacizumab, and proton irradiation demonstrate anti-proliferative effects on resistant melanoma cells.
  • These therapeutic agents induce cell cycle arrest (G1 or G2) and stimulate apoptotic cell death.
  • The combination of these treatments shows potential for managing aggressive and resistant melanoma.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...